Virtu Financial LLC lessened its stake in Pfizer, Inc. (NYSE:PFE) by 21.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,583 shares of the biopharmaceutical company’s stock after selling 3,144 shares during the quarter. Virtu Financial LLC’s holdings in Pfizer were worth $389,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Asset Planning Services Ltd. boosted its position in Pfizer by 4.9% during the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 137 shares in the last quarter. Franklin Parlapiano Turner & Welch LLC acquired a new stake in Pfizer in the first quarter valued at $121,000. Patten Group Inc. grew its holdings in Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock valued at $177,000 after purchasing an additional 252 shares during the last quarter. Kimelman & Baird LLC acquired a new stake in Pfizer in the first quarter valued at $203,000. Finally, Prescott Group Capital Management L.L.C. acquired a new stake in Pfizer in the first quarter valued at $205,000. Institutional investors and hedge funds own 69.00% of the company’s stock.

Several equities research analysts recently commented on PFE shares. Berenberg Bank reiterated a “hold” rating and issued a $36.00 price objective (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a report on Saturday, August 5th. Cowen and Company set a $43.00 target price on shares of Pfizer and gave the company a “buy” rating in a report on Monday, August 14th. UBS AG restated a “buy” rating and set a $38.00 target price on shares of Pfizer in a research report on Monday, July 31st. Finally, Jefferies Group LLC restated a “hold” rating and set a $35.00 target price (up previously from $34.00) on shares of Pfizer in a research report on Friday, July 14th. Two analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $38.04.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $35.00, for a total value of $1,338,050.00. Following the completion of the transaction, the insider now directly owns 145,649 shares in the company, valued at $5,097,715. The disclosure for this sale can be found here. In the last quarter, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is currently owned by corporate insiders.

Pfizer, Inc. (NYSE PFE) traded up 0.92% during trading on Monday, reaching $36.03. 7,908,083 shares of the company’s stock were exchanged. The company’s 50 day moving average price is $33.78 and its 200-day moving average price is $33.53. The stock has a market capitalization of $214.28 billion, a price-to-earnings ratio of 26.36 and a beta of 1.00. Pfizer, Inc. has a 52 week low of $29.83 and a 52 week high of $36.21.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The firm had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period in the prior year, the business posted $0.64 earnings per share. The business’s quarterly revenue was down 1.9% on a year-over-year basis. On average, equities analysts expect that Pfizer, Inc. will post $2.56 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be given a $0.32 dividend. The ex-dividend date of this dividend is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.59%. Pfizer’s dividend payout ratio is currently 94.12%.

TRADEMARK VIOLATION WARNING: “Pfizer, Inc. (PFE) Shares Sold by Virtu Financial LLC” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/02/pfizer-inc-pfe-shares-sold-by-virtu-financial-llc.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.